Moderate-risk patients with diabetes treated with a sulfonylurea appear to be at a higher risk of major adverse cardiovascular events than those who receive a dipeptidyl peptidase-4 (DPP-4) inhibitor, ...
Glipizide/metformin HCl; 2.5mg/250mg, 2.5mg/500mg, 5mg/500mg; tabs. Adjunct to diet and exercise in type 2 diabetes, as initial therapy or as second-line therapy when response to a sulfonylurea or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback